




RealRate

PHARMACEUTICAL 2021

Ernexa Therapeutics Inc
Rank 336 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 280% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 122% points below the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	1,724	Assets	3,745
Cost of Goods Sold	0	Liabilities	2,894
Intangible Assets	0	Expenses	12,103
Liabilities, Current	2,360	Revenues	5,800
Liabilities, Non-Current	532	Stockholders Equity	851
Other Assets	1,519	Net Income	-4,415
Other Compr. Net Income	-23	Comprehensive Net Income	-4,426
Other Expenses	4,012	BaseVar	13,226
Other Liabilities	2.0	ECR before LimitedLiability	-77%
Other Net Income	1,888	Economic Capital Ratio	134%
Other Revenues	5,800		
Property and Equipment	502		
Research and Development	0		
Selling, General and Administrative Expense	8,091		